A Phase 3 interventional study of Seltorexant and Placebo in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Completed at 122 sites in 11 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing seltorexant in Depressive Disorder, Major — 2 open to participants now, 2 under way, 2 of them phase 3. seltorexant · Depressive Disorder, Major.
Among the 12 studies testing seltorexant in Depressive Disorder, Major, this one is the 4th largest by enrollment, is one of 4 that started in 2020, is one of 5 in phase 3, and was the 8th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →2 of the 12 studies testing seltorexant in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Argentina, Brazil and 4 more countries
Ages 18–74
Janssen Research & Development, LLC · Sites in United States, Argentina, Brazil and 13 more countries
Ages 18–74
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 588 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 176 across the 12 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 2 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
59 studies in Depressive Disorder, Major by Johnson & Johnson: 5 open now, 5 under way, 5 of them phase 3. Of 53 finished, 26 (49%) have results posted.
Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 8th largest by enrollment of the 52 interventional ones that give a count, is one of 7 that started in 2020, is one of 23 in phase 3, and was the 38th registered.
Johnson & Johnson’s Depressive Disorder, Major studies by the year they started, since 2002.
1 of the studies testing seltorexant in Depressive Disorder, Major that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing seltorexant in Depressive Disorder, Major, from their registry updates:
Among Johnson & Johnson’s 59 in Depressive Disorder, Major:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with an selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) in double-blind treatment phase and to assess the long-term safety and tolerability of seltorexant as adjunctive therapy to an antidepressant in participants with major depressive disorder (MDD) in open-label treatment phase.
Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for adjunctive treatment of major depressive disorder with insomnia symptoms (MDDIS). The hypothesis for this study is that adjunctive treatment with seltorexant is superior to placebo in treating depressive symptoms, as measured by change in Montgomery Asberg Depression Rating Scale (MADRS) total score from baseline to Day 43 in adult and elderly participants with MDDIS who have had an inadequate response to treatment with a SSRI/SNRI. The study will be conducted in 4 phases: a screening phase (up to 30 days), a double-blind (DB) treatment phase (43 days), open label (OL) treatment phase (1-year), and a post treatment follow-up phase (7 to 14 days after end of treatment). The total study duration for each participant will be up to 64 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at specified time points during this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive seltorexant tablet orally once daily, from Day 1 to Day 42 in double blind (DB) treatment phase. Eligible participants who will enter the open label (OL) treatment phase will receive seltorexant tablet daily from OL baseline until the end of phase/ early withdrawal (EW) visit (Up to 1 Year).
Drug: Seltorexant
Participants will receive matching placebo tablet orally once daily, from Day 1 to Day 42 in double blind (DB) treatment phase.
Drug: Placebo
Seltorexant tablet will be administered orally once daily.
Also known as: JNJ-42847922
Matching placebo tablet will be administered orally once daily.
Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1
The MADRS is a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant intervention. Scale has 10 items(apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts) each of which was scored from 0 (not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score is sum of scores from individual question items, which ranged from 0 to 60. Higher scores indicates more severe condition. Negative changes in MADRS total score indicates improvement.
Time frame: Baseline (Day 1), Day 43
Open Label (OL) Treatment Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participants administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study drug. Treatment emergent AEs was defined as any AE occurred at or after the initial administration of study intervention through the day of last dose plus 2 days.
Time frame: From start of the treatment in OL phase (OL Day 1 [Day 43 from study baseline]) up to 2 days after last dose in OL phase (up to 52.28 weeks)
OL Treatment Phase: Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESI)
AE was defined as any untoward medical occurrence in a clinical study participants administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study drug. Treatment emergent AEs was defined as any AE occurred at or after the initial administration of study intervention through the day of last dose plus 2 days. The AEs considered to be of special interest: cataplexy, sleep paralysis, complex, sleep-related behaviors/parasomnias such as confusional arousals, somnambulism, sleep terrors, bruxism, sleep sex, sleep-related eating disorder, and catathrenia, fall, motor vehicle accident.
Time frame: From start of the treatment in OL phase (OL Day 1 [Day 43 from study baseline]) up to 2 days after last dose in OL phase (up to 52.28 weeks)
OL Treatment Phase: Change From Baseline in Vital Signs: Blood Pressure
Change from baseline in vital signs: systolic/diastolic blood pressure were reported. Blood pressure measurements were assessed with the participant in a sitting position using a completely automated device.
Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
OL Treatment Phase: Change From Baseline: Body Mass Index (BMI)
Change from baseline in BMI were reported.
Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
OL Treatment Phase: Change From Baseline in Vital Signs: Temperature
Change from baseline in vital signs: temperature were reported.
Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
OL Treatment Phase: Change From Baseline in Vital Signs: Pulse Rate
Change from baseline in vital signs: pulse rate were reported. Pulse rate measurements were assessed with the participant in a sitting position using a completely automated device.
Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
OL Treatment Phase: Change From Baseline in Weight
Change from baseline in weight was reported.
Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
OL Treatment Phase: Change From Baseline in Waist Circumference
Change from baseline in waist circumference were reported.
Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
OL Treatment Phase: Number of Participants With Shift From Baseline in Suicidal Ideation and Behavior Using the Columbia Suicide Severity Rating Scale (C-SSRS)
C-SSRS is a clinician-rated instrument that reports severity and frequency of suicide-related ideation and behaviors. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (non-specific active suicidal thoughts), 3 (suicidal ideation without plan and intent), 4 (suicidal ideation intent to act without plan), and 5 (suicidal ideation with plan and intent), Suicidal behavior is classified on a 5-item scale: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt), and 10 (suicide). Total score from 10 categories was summarized into 3 categories: No suicidal ideation or behavior(0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranged from 0 to 10, higher total scores indicate more suicidal ideation and/or suicidal behavior. Categories with at least 1 non-zero data values are reported.
Time frame: From DB Baseline (Day 1) up to Week 52
OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Start of OL Follow Up
The PWC-20 was a simple and accurate method used to assess potential withdrawal symptoms following cessation of treatment. The PWC-20 was a reliable and sensitive instrument for the assessment of discontinuation symptoms. The assessment has 20 items (loss of appetite, nausea-vomiting, diarrhea, anxiety-nervousness, irritability, dysphoric mood-depression, insomnia, fatigue, poor coordination, restlessness, diaphoresis, tremor, dizziness, headaches, muscle aches or stiffness, weakness, increased acuity sound smell touch, paresthesia, difficulty concentrating-remember, depersonalization-derealization) evaluated to detect withdrawal symptoms. Symptoms are rated on a scale: 0-3, 0 =not present, 1=mild, 2 =moderate, and 3 =severe. The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. The higher score indicates more severe symptoms.
Time frame: Start of OL Follow Up (Week 52)
OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 1
The PWC-20 was a simple and accurate method used to assess potential withdrawal symptoms following cessation of treatment. The PWC-20 was a reliable and sensitive instrument for the assessment of discontinuation symptoms. The assessment has 20 items (loss of appetite, nausea-vomiting, diarrhea, anxiety-nervousness, irritability, dysphoric mood-depression, insomnia, fatigue, poor coordination, restlessness, diaphoresis, tremor, dizziness, headaches, muscle aches or stiffness, weakness, increased acuity sound smell touch, paresthesia, difficulty concentrating-remember, depersonalization-derealization) evaluated to detect withdrawal symptoms. Symptoms are rated on a scale: 0-3, 0 =not present, 1=mild, 2 =moderate, and 3 =severe. The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. The higher score indicates more severe symptoms.
Time frame: Follow up Visit 1: 1 day after end of OL phase (Week 52.14)
OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 2
The PWC-20 was a simple and accurate method used to assess potential withdrawal symptoms following cessation of treatment. The PWC-20 was a reliable and sensitive instrument for the assessment of discontinuation symptoms. The assessment has 20 items (loss of appetite, nausea-vomiting, diarrhea, anxiety-nervousness, irritability, dysphoric mood-depression, insomnia, fatigue, poor coordination, restlessness, diaphoresis, tremor, dizziness, headaches, muscle aches or stiffness, weakness, increased acuity sound smell touch, paresthesia, difficulty concentrating-remember, depersonalization-derealization)evaluated to detect withdrawal symptoms. Symptoms are rated on a scale: 0-3, 0 =not present, 1=mild, 2 =moderate, and 3 =severe. The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. The higher score indicates more severe symptoms.
Time frame: Follow Up Visit 2: 2 weeks after end of OL phase (Week 54)
OL Treatment Phase: Number of Participants With Electrocardiogram (ECG) Abnormalities
Number of participants with ECG abnormalities during OL treatment phase was reported. ECG abnormalities were assessed as per investigator's discretion.
Time frame: Week 52
OL Treatment Phase: Number of Participants With Clinically Significant Laboratory Abnormalities
Laboratory parameters: hematology (platelet count, red blood cell \[RBC\] count, hemoglobin, hematocrit, neutrophils (Segmented/Leukocytes), lymphocytes, monocytes, eosinophils/leukocytes \[Eos/Leu\], basophils, Reticulocytes/ Erythrocytes \[Reti/Ery\]); chemistry (sodium, potassium, chloride, bicarbonate, creatinine, Creatine Kinase, glucose, aspartate transaminase \[AST\], alanine transaminase \[ALT\], gamma-glutamyl transferase \[GGT\], alkaline phosphatase, total bilirubin, phosphate, albumin, total protein, total cholesterol, high-density lipoprotein, low-density lipoprotein, Triglycerides); urine (specific gravity, pH, glucose, blood, bilirubin, urobilinogen, RBC). Clinically significant abnormalities (low/high) were determined at the investigator's discretion. Only those categories in which at least one participant had data were reported in this outcome measure.
Time frame: From DB Baseline (Day 1) to Week 52
OL Treatment Phase: Number of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Score
ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Each of the 5 items is rated on a 6-point Likert scale, ranging from 1 to 6. The 5 items are summed to create a total score, ranging from 5 to 30, with the higher scores indicating more sexual dysfunction. Sexual dysfunction is defined as an ASEX total score of 19 or greater, or a score of 5 or greater on any item, or a score of 4 or greater on any 3 items.
Time frame: Week 52
DB Treatment Phase: Change From Baseline to Day 43 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score- Estimand 1
The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. The MADRS-WOSI evaluated apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Negative change in MADRS total score indicated improvement.
Time frame: Baseline (Day 1), Day 43
DB Treatment Phase: Change From Baseline to Day 43 in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (8a) T-Score: Estimand 1
PROMIS-SD Short Form 8a is a static 8-item questionnaire, assessed self-perceptions of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items), worrying about sleep (1 item). Each question has five response options ranging in value from 1 to 5. Direction of responses was not same, sometimes "not at all" represents more sleep disturbance; sometimes "not at all" indicates less sleep disturbance. Total raw score for short form with all questions answered was sum of values of response to each question, total score ranged 8 to 40. Lower scores indicate less sleep disturbance. Total raw score converted into T-score. T-score rescaled the raw score into standardized score with mean: 50; standard deviation: 10. Negative changes in scores indicates improvement. Higher values represent more severe sleep disturbance.
Time frame: Baseline (Day 1), Day 43
DB Treatment Phase: Change From Baseline to Day 43 in the MADRS-6 Total Score: Estimand 1
The 6-item MADRS was a clinician-administered scale designed to measure the core symptoms of depression severity and detected changes due to antidepressant intervention. It is a subset of MADRS (10-item). The MADRS-6 subscale score was the sum of scores for the following MADRS items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item is scored from 0 (item not present or normal) to 6 (most severe or continuous presence of symptoms); the overall score ranges from 0 to 36, higher scores represented a more severe condition. Negative change in score indicates improvement.
Time frame: Baseline (Day 1), Day 43
DB Treatment Phase: Percentage of Participants With Response on Depressive Symptoms Scale Based on MADRS at Day 43
Percentage of participants with response on depressive symptoms scale based on MADRS total score at Day 43 were reported. Responders were defined as participants with a \>=50 percent (%) improvement in the MADRS total score from baseline to a given timepoint. The MADRS is a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant intervention. Scale has 10 items(apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts) each of which was scored from 0 (not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score is sum of scores from individual question items, which ranged from 0 to 60. Higher scores indicates more severe condition. Negative changes in MADRS total score indicates improvement.
Time frame: At Day 43
DB Treatment Phase: Change From Baseline to Day 43 in Patient Health Questionnaire 9-item (PHQ-9) Total Score
The PHQ-9 was a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) MDD criteria. Each item was rated on a 4 points scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses were summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). Negative changes in PHQ-9 total score indicated improvement.
Time frame: Baseline (Day 1), Day 43
OL Treatment Phase: Change From Baseline Over Time in MADRS Total Score
MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms). MADRS total score was sum of scores from individual question items, which ranged from 0-60. Higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.
Time frame: OL Baseline (Day 1 [Day 43 from study baseline]), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
OL Treatment Phase: Change From Baseline Over Time in the Clinical Global Impression-Severity (CGI-S) Score
The CGI-S (depression) provided an overall clinician-determined summary measure of severity of the participant's illness that considers all available information, included knowledge of participant's history, psychosocial circumstances, symptoms, behavior, impact of symptoms on participant's ability to function. CGI-S evaluated severity of psychopathology on a scale of 1 to 7. The CGI-S was 7-point global assessment scale that measures clinician's impression of severity of illness, rating: 1=normal (not at all ill), 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill participants, with higher scores indicate worsening. Negative changes in CGI-S score indicate improvement.
Time frame: OL Baseline (Day 1 [Day 43 from study baseline]), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
OL Treatment Phase: Change From Baseline Over Time in the MADRS-WOSI Total Score
The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. The MADRS-WOSI evaluated apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Negative change in MADRS total score indicated improvement.
Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
OL Treatment Phase: Change From Baseline Over Time in Sleep Disturbance Using the PROMIS-SD Short Form 8a T-Score
PROMIS-SD Short Form 8a is a static 8-item questionnaire, assessed self-perceptions of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items), worrying about sleep (1 item). Each question has five response options ranging in value from one to five. Direction of responses was not same, sometimes "not at all" represents more sleep disturbance; sometimes "not at all" indicates less sleep disturbance. Total raw score for short form with all questions answered was sum of values of response to each question, total score ranged 8 to 40. Lower scores indicate less sleep disturbance. Total raw score converted into T-score. T-score rescaled the raw score into standardized score with mean:50; standard deviation:10. Negative changes in scores indicates improvement. Higher values represent more severe sleep disturbance.
Time frame: OL Baseline (OL Day 1 [Day 43 from study baseline]), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
| Milestone | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg | DB Follow-up Phase: Placebo | DB Follow-up Phase: Seltorexant 20 mg | OL Follow-up Phase: Placebo to Seltorexant 20 mg | OL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|---|---|---|---|---|---|
| Started | 304 | 284 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treated | 303 | 283 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 277 | 263 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 27 | 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 11 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Initiated prohibited medication | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with primary antidepressant | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized but not treated | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg | DB Follow-up Phase: Placebo | DB Follow-up Phase: Seltorexant 20 mg | OL Follow-up Phase: Placebo to Seltorexant 20 mg | OL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 269 | 253 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 176 | 184 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 93 | 69 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 22 | 11 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 12 | 10 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 8 | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 36 | 28 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 6 | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Initiated prohibited medication | 0 | 0 | 3 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with primary antidepressant | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Site terminated by sponsor | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| Milestone | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg | DB Follow-up Phase: Placebo | DB Follow-up Phase: Seltorexant 20 mg | OL Follow-up Phase: Placebo to Seltorexant 20 mg | OL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 22 | 22 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 18 | 15 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 4 | 7 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 2 | 4 | 0 | 0 |
| Milestone | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg | DB Follow-up Phase: Placebo | DB Follow-up Phase: Seltorexant 20 mg | OL Follow-up Phase: Placebo to Seltorexant 20 mg | OL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 228 | 225 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 214 | 211 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 14 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 8 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| Withdrew: Site terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
The MADRS is a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant intervention. Scale has 10 items(apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts) each of which was scored from 0 (not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score is sum of scores from individual question items, which ranged from 0 to 60. Higher scores indicates more severe condition. Negative changes in MADRS total score indicates improvement.
| Units on a scale | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg |
|---|---|---|
| Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1 | -10.5 ± 10.26 | -12.9 ± 9.63 |
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participants administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study drug. Treatment emergent AEs was defined as any AE occurred at or after the initial administration of study intervention through the day of last dose plus 2 days.
| Participants | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| Open Label (OL) Treatment Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 167 | 163 |
AE was defined as any untoward medical occurrence in a clinical study participants administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study drug. Treatment emergent AEs was defined as any AE occurred at or after the initial administration of study intervention through the day of last dose plus 2 days. The AEs considered to be of special interest: cataplexy, sleep paralysis, complex, sleep-related behaviors/parasomnias such as confusional arousals, somnambulism, sleep terrors, bruxism, sleep sex, sleep-related eating disorder, and catathrenia, fall, motor vehicle accident.
| Participants | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| OL Treatment Phase: Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESI) | 10 | 8 |
Change from baseline in vital signs: systolic/diastolic blood pressure were reported. Blood pressure measurements were assessed with the participant in a sitting position using a completely automated device.
| Millimeters of mercury (mmHg) | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| Diastolic Blood Pressure | 0.1 ± 8.22 | 0.9 ± 8.38 |
| Systolic Blood Pressure | 0.5 ± 10.38 | -0.5 ± 11.29 |
Change from baseline in BMI were reported.
| Kilogram per square meter(kg/m^2) | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| OL Treatment Phase: Change From Baseline: Body Mass Index (BMI) | 0.44 ± 1.589 | 0.67 ± 1.673 |
Change from baseline in vital signs: temperature were reported.
| Degree Celsius (C) | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| OL Treatment Phase: Change From Baseline in Vital Signs: Temperature | -0.03 ± 0.313 | 0.01 ± 0.300 |
Change from baseline in vital signs: pulse rate were reported. Pulse rate measurements were assessed with the participant in a sitting position using a completely automated device.
| Beats/min | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| OL Treatment Phase: Change From Baseline in Vital Signs: Pulse Rate | 0.1 ± 8.28 | 0.5 ± 9.31 |
Change from baseline in weight was reported.
| Kilogram (Kg) | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| OL Treatment Phase: Change From Baseline in Weight | 1.26 ± 4.303 | 1.80 ± 4.567 |
Change from baseline in waist circumference were reported.
| Centimeter (Cm) | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| OL Treatment Phase: Change From Baseline in Waist Circumference | 0.5 ± 5.95 | 0.7 ± 5.95 |
C-SSRS is a clinician-rated instrument that reports severity and frequency of suicide-related ideation and behaviors. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (non-specific active suicidal thoughts), 3 (suicidal ideation without plan and intent), 4 (suicidal ideation intent to act without plan), and 5 (suicidal ideation with plan and intent), Suicidal behavior is classified on a 5-item scale: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt), and 10 (suicide). Total score from 10 categories was summarized into 3 categories: No suicidal ideation or behavior(0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranged from 0 to 10, higher total scores indicate more suicidal ideation and/or suicidal behavior. Categories with at least 1 non-zero data values are reported.
| Participants | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| Baseline: No SI/SB to Postbaseline No SI/SB | 204 | 190 |
| Baseline: No SI/SB to Postbaseline Suicidal Ideation | 18 | 15 |
| Baseline: No SI/SB to Postbaseline Suicidal Behavior | 4 | 0 |
| Baseline: Suicidal ideation to Postbaseline No SI/SB | 18 | 16 |
| Baseline: Suicidal ideation to Postbaseline Suicidal Ideation | 24 | 30 |
| Baseline: Suicidal ideation to Postbaseline Suicidal Behavior | 1 | 2 |
The PWC-20 was a simple and accurate method used to assess potential withdrawal symptoms following cessation of treatment. The PWC-20 was a reliable and sensitive instrument for the assessment of discontinuation symptoms. The assessment has 20 items (loss of appetite, nausea-vomiting, diarrhea, anxiety-nervousness, irritability, dysphoric mood-depression, insomnia, fatigue, poor coordination, restlessness, diaphoresis, tremor, dizziness, headaches, muscle aches or stiffness, weakness, increased acuity sound smell touch, paresthesia, difficulty concentrating-remember, depersonalization-derealization) evaluated to detect withdrawal symptoms. Symptoms are rated on a scale: 0-3, 0 =not present, 1=mild, 2 =moderate, and 3 =severe. The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. The higher score indicates more severe symptoms.
| Units on a scale | OL Follow-up Phase: Placebo to Seltorexant 20 mg | OL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Start of OL Follow Up | 7.8 ± 8.48 | 7.4 ± 8.27 |
The PWC-20 was a simple and accurate method used to assess potential withdrawal symptoms following cessation of treatment. The PWC-20 was a reliable and sensitive instrument for the assessment of discontinuation symptoms. The assessment has 20 items (loss of appetite, nausea-vomiting, diarrhea, anxiety-nervousness, irritability, dysphoric mood-depression, insomnia, fatigue, poor coordination, restlessness, diaphoresis, tremor, dizziness, headaches, muscle aches or stiffness, weakness, increased acuity sound smell touch, paresthesia, difficulty concentrating-remember, depersonalization-derealization) evaluated to detect withdrawal symptoms. Symptoms are rated on a scale: 0-3, 0 =not present, 1=mild, 2 =moderate, and 3 =severe. The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. The higher score indicates more severe symptoms.
| Units on a scale | OL Follow-up Phase: Placebo to Seltorexant 20 mg | OL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 1 | 6.2 ± 7.62 | 5.5 ± 7.04 |
The PWC-20 was a simple and accurate method used to assess potential withdrawal symptoms following cessation of treatment. The PWC-20 was a reliable and sensitive instrument for the assessment of discontinuation symptoms. The assessment has 20 items (loss of appetite, nausea-vomiting, diarrhea, anxiety-nervousness, irritability, dysphoric mood-depression, insomnia, fatigue, poor coordination, restlessness, diaphoresis, tremor, dizziness, headaches, muscle aches or stiffness, weakness, increased acuity sound smell touch, paresthesia, difficulty concentrating-remember, depersonalization-derealization)evaluated to detect withdrawal symptoms. Symptoms are rated on a scale: 0-3, 0 =not present, 1=mild, 2 =moderate, and 3 =severe. The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. The higher score indicates more severe symptoms.
| Units on a scale | OL Follow-up Phase: Placebo to Seltorexant 20 mg | OL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 2 | 6.3 ± 6.76 | 7.1 ± 8.04 |
Number of participants with ECG abnormalities during OL treatment phase was reported. ECG abnormalities were assessed as per investigator's discretion.
| Participants | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| OL Treatment Phase: Number of Participants With Electrocardiogram (ECG) Abnormalities | 27 | 26 |
Laboratory parameters: hematology (platelet count, red blood cell \[RBC\] count, hemoglobin, hematocrit, neutrophils (Segmented/Leukocytes), lymphocytes, monocytes, eosinophils/leukocytes \[Eos/Leu\], basophils, Reticulocytes/ Erythrocytes \[Reti/Ery\]); chemistry (sodium, potassium, chloride, bicarbonate, creatinine, Creatine Kinase, glucose, aspartate transaminase \[AST\], alanine transaminase \[ALT\], gamma-glutamyl transferase \[GGT\], alkaline phosphatase, total bilirubin, phosphate, albumin, total protein, total cholesterol, high-density lipoprotein, low-density lipoprotein, Triglycerides); urine (specific gravity, pH, glucose, blood, bilirubin, urobilinogen, RBC). Clinically significant abnormalities (low/high) were determined at the investigator's discretion. Only those categories in which at least one participant had data were reported in this outcome measure.
| Participants | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| ALT High | 1 | 2 |
| AST High | 0 | 1 |
| Bicarbonate Low | 1 | 0 |
| Chloride Low | 1 | 0 |
| Cholesterol High | 7 | 11 |
| Creatine Kinase High | 4 | 6 |
| GGT High | 1 | 0 |
| Glucose High | 1 | 0 |
| HDL Cholesterol low | 19 | 24 |
| Hemoglobin A1C/ Hemoglobin High | 2 | 3 |
| LDL Cholesterol Low | 44 | 41 |
| LDL Cholesterol High | 54 | 36 |
| Phosphate low | 2 | 6 |
| Potassium Low | 1 | 1 |
| Potassium High | 2 | 1 |
| Triglycerides High | 1 | 0 |
| Eos/Leu High | 2 | 3 |
| Erythrocytes High | 1 | 4 |
| Hematocrit High | 3 | 5 |
| Leukocytes Low | 1 | 0 |
| Leukocytes High | 3 | 1 |
| Lymphocytes/Leukocytes High | 2 | 0 |
| Lymphocytes/Leukocytes Low | 1 | 5 |
| Neutrophils low | 4 | 1 |
| Neutrophils High | 0 | 1 |
| Platelets Low | 0 | 1 |
| Platelets High | 0 | 2 |
| Reti/Ery Low | 3 | 3 |
| Reti/Ery High | 73 | 63 |
| Specific Gravity High | 25 | 22 |
| Urine pH High | 24 | 32 |
ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Each of the 5 items is rated on a 6-point Likert scale, ranging from 1 to 6. The 5 items are summed to create a total score, ranging from 5 to 30, with the higher scores indicating more sexual dysfunction. Sexual dysfunction is defined as an ASEX total score of 19 or greater, or a score of 5 or greater on any item, or a score of 4 or greater on any 3 items.
| Participants | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| OL Treatment Phase: Number of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Score | 124 | 111 |
The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. The MADRS-WOSI evaluated apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Negative change in MADRS total score indicated improvement.
| Units on a scale | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg |
|---|---|---|
| DB Treatment Phase: Change From Baseline to Day 43 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score- Estimand 1 | -9.5 ± 9.38 | -11.4 ± 8.77 |
PROMIS-SD Short Form 8a is a static 8-item questionnaire, assessed self-perceptions of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items), worrying about sleep (1 item). Each question has five response options ranging in value from 1 to 5. Direction of responses was not same, sometimes "not at all" represents more sleep disturbance; sometimes "not at all" indicates less sleep disturbance. Total raw score for short form with all questions answered was sum of values of response to each question, total score ranged 8 to 40. Lower scores indicate less sleep disturbance. Total raw score converted into T-score. T-score rescaled the raw score into standardized score with mean: 50; standard deviation: 10. Negative changes in scores indicates improvement. Higher values represent more severe sleep disturbance.
| T-score | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg |
|---|---|---|
| DB Treatment Phase: Change From Baseline to Day 43 in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (8a) T-Score: Estimand 1 | -7.2 ± 10.60 | -10.9 ± 9.14 |
The 6-item MADRS was a clinician-administered scale designed to measure the core symptoms of depression severity and detected changes due to antidepressant intervention. It is a subset of MADRS (10-item). The MADRS-6 subscale score was the sum of scores for the following MADRS items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item is scored from 0 (item not present or normal) to 6 (most severe or continuous presence of symptoms); the overall score ranges from 0 to 36, higher scores represented a more severe condition. Negative change in score indicates improvement.
| Units on a scale | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg |
|---|---|---|
| DB Treatment Phase: Change From Baseline to Day 43 in the MADRS-6 Total Score: Estimand 1 | -7.1 ± 7.06 | -8.4 ± 6.79 |
Percentage of participants with response on depressive symptoms scale based on MADRS total score at Day 43 were reported. Responders were defined as participants with a \>=50 percent (%) improvement in the MADRS total score from baseline to a given timepoint. The MADRS is a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant intervention. Scale has 10 items(apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts) each of which was scored from 0 (not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score is sum of scores from individual question items, which ranged from 0 to 60. Higher scores indicates more severe condition. Negative changes in MADRS total score indicates improvement.
| Percentage of Participants | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg |
|---|---|---|
| DB Treatment Phase: Percentage of Participants With Response on Depressive Symptoms Scale Based on MADRS at Day 43 | 22.9 | 35.4 |
The PHQ-9 was a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) MDD criteria. Each item was rated on a 4 points scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses were summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). Negative changes in PHQ-9 total score indicated improvement.
| Units on a scale | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg |
|---|---|---|
| DB Treatment Phase: Change From Baseline to Day 43 in Patient Health Questionnaire 9-item (PHQ-9) Total Score | -5.6 ± 6.62 | -7.6 ± 6.03 |
MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms). MADRS total score was sum of scores from individual question items, which ranged from 0-60. Higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.
| Score on a scale | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| Week 4 | -6.2 ± 8.48 | -3.8 ± 7.91 |
| Week 8 | -7.7 ± 10.03 | -4.7 ± 8.78 |
| Week 12 | -8.4 ± 10.04 | -5.3 ± 9.51 |
| Week 16 | -9.5 ± 10.28 | -6.1 ± 10.29 |
| Week 20 | -9.8 ± 10.81 | -7.4 ± 10.14 |
| Week 24 | -9.3 ± 11.67 | -6.9 ± 10.07 |
| Week 28 | -10.4 ± 11.31 | -7.3 ± 10.57 |
| Week 32 | -11.2 ± 11.87 | -7.9 ± 10.37 |
| Week 36 | -10.4 ± 12.47 | -8.3 ± 10.11 |
| Week 40 | -11.2 ± 11.96 | -9.2 ± 10.90 |
| Week 44 | -12.2 ± 11.62 | -9.9 ± 10.15 |
| Week 48 | -12.3 ± 11.51 | -10.2 ± 9.66 |
| Week 52 | -12.3 ± 11.37 | -10.5 ± 9.42 |
The CGI-S (depression) provided an overall clinician-determined summary measure of severity of the participant's illness that considers all available information, included knowledge of participant's history, psychosocial circumstances, symptoms, behavior, impact of symptoms on participant's ability to function. CGI-S evaluated severity of psychopathology on a scale of 1 to 7. The CGI-S was 7-point global assessment scale that measures clinician's impression of severity of illness, rating: 1=normal (not at all ill), 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill participants, with higher scores indicate worsening. Negative changes in CGI-S score indicate improvement.
| Score on a scale | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| Week 4 | -0.7 ± 1.05 | -0.4 ± 0.91 |
| Week 8 | -1.0 ± 1.15 | -0.6 ± 1.05 |
| Week 12 | -1.0 ± 1.22 | -0.7 ± 1.18 |
| Week 16 | -1.2 ± 1.32 | -0.8 ± 1.33 |
| Week 20 | -1.2 ± 1.36 | -0.9 ± 1.32 |
| Week 24 | -1.2 ± 1.46 | -0.9 ± 1.32 |
| Week 28 | -1.3 ± 1.45 | -1.0 ± 1.34 |
| Week 32 | -1.5 ± 1.37 | -1.1 ± 1.33 |
| Week 36 | -1.4 ± 1.50 | -1.1 ± 1.43 |
| Week 40 | -1.5 ± 1.46 | -1.2 ± 1.44 |
| Week 44 | -1.6 ± 1.49 | -1.4 ± 1.35 |
| Week 48 | -1.7 ± 1.47 | -1.4 ± 1.30 |
| Week 52 | -1.7 ± 1.44 | -1.4 ± 1.30 |
The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. The MADRS-WOSI evaluated apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Negative change in MADRS total score indicated improvement.
| Score on a scale | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| Week 4 | -5.0 ± 7.74 | -3.3 ± 7.12 |
| Week 8 | -6.4 ± 9.16 | -4.2 ± 7.76 |
| Week 12 | -7.0 ± 9.15 | -4.7 ± 8.55 |
| Week 16 | -8.0 ± 9.34 | -5.3 ± 9.30 |
| Week 20 | -8.3 ± 9.89 | -6.7 ± 9.07 |
| Week 24 | -7.8 ± 10.82 | -6.2 ± 9.02 |
| Week 28 | -8.9 ± 10.39 | -6.5 ± 9.58 |
| Week 32 | -9.7 ± 10.86 | -7.0 ± 9.52 |
| Week 36 | -8.9 ± 11.28 | -7.4 ± 9.07 |
| Week 40 | -9.5 ± 11.01 | -8.2 ± 9.87 |
| Week 44 | -10.5 ± 10.73 | -8.8 ± 8.96 |
| Week 48 | -10.6 ± 10.56 | -9.3 ± 8.66 |
| Week 52 | -10.4 ± 10.29 | -9.3 ± 8.35 |
PROMIS-SD Short Form 8a is a static 8-item questionnaire, assessed self-perceptions of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items), worrying about sleep (1 item). Each question has five response options ranging in value from one to five. Direction of responses was not same, sometimes "not at all" represents more sleep disturbance; sometimes "not at all" indicates less sleep disturbance. Total raw score for short form with all questions answered was sum of values of response to each question, total score ranged 8 to 40. Lower scores indicate less sleep disturbance. Total raw score converted into T-score. T-score rescaled the raw score into standardized score with mean:50; standard deviation:10. Negative changes in scores indicates improvement. Higher values represent more severe sleep disturbance.
| T-score | Open-label (OL) Treatment Phase: Placebo to Seltorexant 20 mg | OL Treatment Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|
| Week 4 | -6.9 ± 8.58 | -2.8 ± 8.07 |
| Week 8 | -7.0 ± 8.77 | -3.5 ± 9.34 |
| Week 12 | -7.9 ± 9.34 | -4.7 ± 9.37 |
| Week 16 | -8.3 ± 9.92 | -4.6 ± 10.23 |
| Week 20 | -8.7 ± 10.33 | -5.0 ± 9.95 |
| Week 24 | -8.5 ± 10.26 | -5.1 ± 9.47 |
| Week 28 | -9.3 ± 10.13 | -5.1 ± 9.65 |
| Week 32 | -8.9 ± 10.40 | -5.7 ± 10.03 |
| Week 36 | -9.2 ± 11.49 | -6.1 ± 9.66 |
| Week 40 | -10.1 ± 10.34 | -6.4 ± 10.30 |
| Week 44 | -11.3 ± 11.29 | -7.1 ± 9.42 |
| Week 48 | -10.5 ± 10.77 | -6.8 ± 9.81 |
| Week 52 | -11.3 ± 10.80 | -8.0 ± 9.86 |
Collected over All-cause mortality: double blind (DB): Screening (Day -30) to Day 44, Open label (OL): Day 43 to 2 days post last dose (Week 52.28), Double blind follow up (DB FU): Day 43 to Day 57, Open label follow up (OL FU): Week 52 to Week 54; SAEs/other AEs: DB: Day 1 to 2 days post last dose (Day 44), OL: Day 43 to 2 days after last dose (Week 52.28), DB FU: Day 43 to Day 57, OL FU: Week 52 to Week 54. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double Blind (DB) Treatment Phase: Placebo | 0/304 (0%) | 1/303 (0.3%) | 39/303 (12.9%) |
| DB Treatment Phase: Seltorexant 20 mg | 0/284 (0%) | 1/283 (0.4%) | 42/283 (14.8%) |
| OL Treatment Phase: Placebo to Seltorexant 20 mg | 0/269 (0%) | 15/269 (5.6%) | 86/269 (32%) |
| OL Phase: Seltorexant 20 mg to Seltorexant 20 mg | 1/253 (0.4%) | 14/253 (5.5%) | 90/253 (35.6%) |
| DB Follow-up Phase: Placebo | 0/22 (0%) | 0/22 (0%) | 1/22 (4.5%) |
| DB Follow-up Phase: Seltorexant 20 mg | 0/22 (0%) | 0/22 (0%) | 0/22 (0%) |
| OL Follow-up Phase: Placebo to Seltorexant 20 mg | 0/228 (0%) | 0/228 (0%) | 4/228 (1.8%) |
| OL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg | 0/225 (0%) | 0/225 (0%) | 6/225 (2.7%) |
| Event | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg | OL Treatment Phase: Placebo to Seltorexant 20 mg | OL Phase: Seltorexant 20 mg to Seltorexant 20 mg | DB Follow-up Phase: Placebo | DB Follow-up Phase: Seltorexant 20 mg | OL Follow-up Phase: Placebo to Seltorexant 20 mg | OL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|---|---|---|---|---|---|
| Suicide AttemptPsychiatric disorders | 0/303 | 0/283 | 5/269 | 2/253 | 0/22 | 0/22 | 0/228 | 0/225 |
| TachycardiaCardiac disorders | 0/303 | 0/283 | 0/269 | 1/253 | 0/22 | 0/22 | 0/228 | 0/225 |
| Optic Nerve Sheath HaemorrhageEye disorders | 0/303 | 0/283 | 0/269 | 1/253 | 0/22 | 0/22 | 0/228 | 0/225 |
| Lower Gastrointestinal HaemorrhageGastrointestinal disorders | 0/303 | 0/283 | 0/269 | 1/253 | 0/22 | 0/22 | 0/228 | 0/225 |
| Chest PainGeneral disorders | 0/303 | 0/283 | 0/269 | 1/253 | 0/22 | 0/22 | 0/228 | 0/225 |
| SepsisInfections and infestations | 0/303 | 0/283 | 0/269 | 1/253 | 0/22 | 0/22 | 0/228 | 0/225 |
| Septic ShockInfections and infestations | 0/303 | 0/283 | 0/269 | 1/253 | 0/22 | 0/22 | 0/228 | 0/225 |
| ConcussionInjury, poisoning and procedural complications | 0/303 | 0/283 | 0/269 | 1/253 | 0/22 | 0/22 | 0/228 | 0/225 |
| Skin LacerationInjury, poisoning and procedural complications | 0/303 | 0/283 | 0/269 | 1/253 | 0/22 | 0/22 | 0/228 | 0/225 |
| Transaminases IncreasedInvestigations | 0/303 | 0/283 | 0/269 | 1/253 | 0/22 | 0/22 | 0/228 | 0/225 |
| Event | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg | OL Treatment Phase: Placebo to Seltorexant 20 mg | OL Phase: Seltorexant 20 mg to Seltorexant 20 mg | DB Follow-up Phase: Placebo | DB Follow-up Phase: Seltorexant 20 mg | OL Follow-up Phase: Placebo to Seltorexant 20 mg | OL Follow-up Phase: Seltorexant 20 mg to Seltorexant 20 mg |
|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 27/303 | 25/283 | 28/269 | 34/253 | 0/22 | 0/22 | 1/228 | 5/225 |
| Covid-19Infections and infestations | 5/303 | 9/283 | 28/269 | 18/253 | 1/22 | 0/22 | 2/228 | 1/225 |
| NasopharyngitisInfections and infestations | 4/303 | 4/283 | 22/269 | 22/253 | 0/22 | 0/22 | 1/228 | 0/225 |
| Weight IncreasedInvestigations | 4/303 | 5/283 | 13/269 | 21/253 | 0/22 | 0/22 | 0/228 | 0/225 |
| InfluenzaInfections and infestations | 4/303 | 1/283 | 11/269 | 14/253 | 0/22 | 0/22 | 0/228 | 0/225 |
Safety (DB) analysis set included all randomized participants who received at least 1 dose of study intervention in the DB phase.
| Age, Categorical(Participants) | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 271 | 264 | 535 |
| >=65 years | 32 | 19 | 51 |
| Age, Continuous(years) | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg | Total |
|---|---|---|---|
| Mean | 45.9 ± 14.28 | 44.3 ± 13.99 | 45.1 ± 14.15 |
| Sex: Female, Male(Participants) | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg | Total |
|---|---|---|---|
| Female | 232 | 217 | 449 |
| Male | 71 | 66 | 137 |
| Ethnicity (NIH/OMB)(Participants) | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 82 | 75 | 157 |
| Not Hispanic or Latino | 220 | 206 | 426 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Race (NIH/OMB)(Participants) | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 15 | 13 | 28 |
| Asian | 12 | 10 | 22 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 15 | 16 | 31 |
| White | 232 | 220 | 452 |
| More than one race | 2 | 1 | 3 |
| Unknown or Not Reported | 26 | 22 | 48 |
| Region of Enrollment(Participants) | Double Blind (DB) Treatment Phase: Placebo | DB Treatment Phase: Seltorexant 20 mg | Total |
|---|---|---|---|
| Brazil | 49 | 40 | 89 |
| Bulgaria | 40 | 37 | 77 |
| Colombia | 22 | 19 | 41 |
| Czech Republic | 39 | 39 | 78 |
| Mexico | 15 | 15 | 30 |
| Russian Federation | 11 | 10 | 21 |
| South Africa | 9 | 9 | 18 |
| Spain | 13 | 13 | 26 |
| Sweden | 36 | 34 | 70 |
| Taiwan | 10 | 9 | 19 |
| United States | 59 | 58 | 117 |
Showing the first 100 of 122 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Sep 2020 to primary completion in Apr 2023, 31 months.
Results were first posted in May 2026, 3 years after primary completion. A results delay was requested in Apr 2024.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 31 months is above that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Seltorexant
Janssen Research & Development, LLC →